Petra Acquisition, Inc.

Status: Deal Closed
U=S+W W=S@11.5
IPO Proceeds, $M $72.78M
IPO Date Oct 8, 2020
CEO Andreas Typaldos
Left Lead LifeSci Capital
IPO Cash in Trust 101.3%
SPAC Tenor 12+1+1+1
IPO Sector Healthcare
IPO Geography Global
Target Company Revelation Biosciences, Inc.
Deal Announced Aug 30, 2021
Deal Size, $M $127.70M
Deal Sector Healthcare
Deal Geography US/Canada
SEC Filings www.sec.gov
Approval Vote Jan 6, 2022
Amendment Vote TBD
Closing Date Jan 10, 2022
Formerly PAIC REVB REVBW

Sign up for Free Trial

No credit card required

Sign in for more on Petra Acquisition, Inc.:

  • Structure and cap table
  • 7 directors & officers
  • 30 filings and events
  • 4 underwriters
  • 2 deal advisors
  • 3 legal advisors
Structure

Sign in to view structure, cap table, and calendar of events.

Team
Name Age Title
Andreas Typaldos 74 Chairman, CEO and Secretary
Sean Fitzpatrick 51 CFO and Director
David Dobkin 41 Director
Anthony Hayes 52 Director
Robert Nicholson 55 Director
Barry Dennis 55 Director
William H. Carson 73 Director

Sign in to view team biographies and more sponsor and affiliate data.

Advisors
Underwriters
LifeSci Capital Joint BR 2,000,000 units
Ladenburg Thalmann Joint BR 2,450,000
Northland Capital Markets 1,400,000
Ingalls & Snyder 1,150,000
7,000,000 units
Up-Front UW fee 2.00 %
BCMA 4.00 %

Sign in to view more advisor data.

Deal

Sign in to view merger details and deal financials.

Filings

Sign in to view 30 filings.

Shareholders

Sign in to view shareholders 13F filing data.